Navigation Links
Watch Harvey up his Game with Hormone Therapy
Date:11/19/2012

MIAMI, Nov. 19, 2012 /PRNewswire/ -- AAG Health & Wellness, a recognized leader in hormone replacement therapy for men, is excited to announce the release of a video that follows the trials and tribulations of a client over the course of his first six month hormone treatment plan.

(Photo: http://photos.prnewswire.com/prnh/20121119/FL15499 )

Watch: Harvey's story. His hormone therapy experience.

The video's subject is a 61 year Miami Beach executive named Harvey who turns to AAG Health for help to get his busy life back on track. After years of declining energy, loss of libido and lack of motivation, Harvey is determined to take action to improve his quality of life and regain peak performance.

"I just got to a point where I said enough is enough. I couldn't keep up with my kids, I wasn't getting results from my workouts, I wasn't paying enough attention to my business and I wanted to get back in the dating scene," explained Harvey, father of 3 children and recently divorced.

The video starts with Harvey going to AAG Health's Age Management center in Miami for his initial evaluation and then goes on to document his progress from month one through month six.

"This is a unique account of how an otherwise healthy man, who is experiencing issues associated with low hormones, reacts to a progressive hormone therapy program that incorporates exercise and good diet," says Frank Welch MD, one of Harvey's treating physicians at AAG Health.

"Harvey came to us wanting to get back the vitality and vigor he had so he could accomplish more. I think we certainly delivered what he was looking for." Dr. Welch continues, "We've treated thousands of men over the past ten years and we're delighted to showcase another success story in this video."


'/>"/>
SOURCE AAG Health & Wellness
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Metabolex Gout Program Recognized in Windhovers Top 10 Most Interesting Projects to Watch
2. POSITIVEID In Businessweek For Bid On U$5.7 Billion BIOWATCH Program
3. Astrix Technology Group Awarded Department of Homeland Security BioWatch Laboratory Staffing Contract
4. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
5. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
6. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
7. PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
8. Gene Therapy - Technologies, Markets and Companies
9. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
10. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
11. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... Aug. 31, 2014 Wockhardt Limited today announces ... in Anti-Infective research when two of its drugs, WCK ... Disease Product (QIDP) status from U.S. Food & Drug ... act against pathogens which have a high degree of ... Centre for Disease Control (a top U.S. government health ...
(Date:8/29/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... difficult to manufacture proteins including biosimilar therapeutics, today ... for the second quarter ended June 30, 2014. ... initial public offering, we have the capital to ... from our proprietary protein expression platform," stated Bertrand ...
(Date:8/29/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the six months ended June 30, 2014. ... dollars and presented under International Financial Reporting Standards ... , Announced top-line results related to the ... subjects enrolled in the Phase 2 iDEAL Study ...
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... 11 AtriCure, Inc.,(Nasdaq: ATRC ), a ... surgical,ablation products, today announced that the first patient ... Richard Kaplon, a,well-known cardiac surgeon, performed the procedure ... purpose of the ABLATE clinical trial is to ...
... 11, Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA ... ), announced today that,they have entered into a ... Possis Medical in a cash tender offer for ... of approximately US-Dollar 361,million. The offer price represents ...
... Ltd. announced that the,quantitative analysis of Replikin Count(TM) ... H5N1 cycle is over. Sporadic outbreaks may,continue, but ... expected to subside - until the next rapid ... begins., 140,000 virus protein sequences were analyzed ...
Cached Biology Technology:AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 2AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6FluForecast(R) Replikin Count(TM) Predicts That the H5N1 Cycle Which Began in 1996 Is Now Over 2
(Date:9/1/2014)... The week-long discussions and decisions of the Nomenclature Section ... Melbourne, Australia in July 2011. This meeting is held ... premier experts on the rules for naming algae, fungi ... rule book for naming the organisms they study. This ... Code of Nomenclature for algae, fungi, and plants, which ...
(Date:8/31/2014)... bacteria C. diff , that causes diarrhoea, temperature ... at the University of Leicester. , Using a mass ... possible to identify the unique ,smell, of C. ... the condition., What is more, the Leicester team say ... the disease simply from their smell a chemical ...
(Date:8/31/2014)... the last 19 years reveals that fresh water from melting ... to rise by 2cm more than the global average of ... rapid rise in sea-level by studying satellite scans of a ... , The melting of the Antarctic ice sheet and ... of around 350 gigatonnes of freshwater to the surrounding ocean. ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
... been inspiring debate across the scientific community since the ... wider discussion about open access publishing has advanced to ... its first few articles (please see http://f1000research.com/articles ). ... further articles will be published on the current consultation ...
... have long known that the body rids itself of excess ... liver and excreting them through the liver,s bile. However, a ... 22 in PLoS ONE suggests that when this ... A molecule sequesters only that mineral and routes it from ...
... new genetic mutation that causes familial amyotrophic lateral sclerosis ... Gehrig,s Disease, has been identified by a team of ... Medical School (UMMS). Mutations to the profilin (PFN1) gene, ... nerve cell axons, is estimated to account for one ...
Cached Biology News:First articles now live on F1000 Research 2First articles now live on F1000 Research 3Copper's previously unknown exit strategy 2Copper's previously unknown exit strategy 3UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 2UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 3
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
... applications for the use of small interfering ... via the RNA interference (RNAi) pathway have ... molecular biology fields. siRNA for experimental use ... or enzymatically, and then transfected into the ...
... The 820-MS features Varians unique ... provides simple, routine removal of troublesome ... more flexible interference-free analysis without the ... quadrupole ion guides, or cells. And, ...
Acetylcholinesterase (human brain, AChE)...
Biology Products: